Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Trevi Therapeutics has finished enrolling subjects in a trial of investigational Haduvio for treating chronic cough in IPF ...

A Corporate presentation is available for in-person conference attendees. About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the ...

The business’s 50-day moving average price is $4.09 and its 200-day moving average price is $3.41. Trevi Therapeutics has a 12 month low of $2.30 and a 12 month high of $5.05. About Trevi ...

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research note issued to investors on Monday ...

JonesTrading analyst Debanjana Chatterjee reiterated a Hold rating on Spyre Therapeutics (SYRE – Research Report) today. The company’s shares ...

In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.